New rabies prevention treatment also works in kids: study.
“Getting bitten by a dog or wild animal is frightening, especially for kids, but a new study may help relieve some of the worry about catching rabies.“
The following written content by Robert Preidt
TUESDAY, Feb. 16, 2021 (HealthDay News) — Getting bitten by a dog or wild animal is frightening, especially for kids, but a new study may help relieve some of the worry about catching rabies.
The rabies prevention treatment KEDRAB is safe and effective for patients 17 and younger, a groundbreaking pediatric clinical trial has shown.
The trial included 30 kids with suspected or confirmed rabies exposure who were treated with KEDRAB (Rabies Immune Globulin [Human]) and followed for 84 days.
KEDRAB was put into and around detectable wounds and/or given intramuscularly along with the first of a four-dose series of rabies vaccine.
None of the patients developed an active rabies infection, and there were no deaths or serious side effects, the researchers reported.
Seven in 10 did have mild side effects, according to findings published Feb. 10 in the journal Human Vaccines & Immunotherapeutics.
This is the first human rabies immunoglobulin shown to be safe and effective in children when used immediately as part of post-exposure disease prevention, the study authors said.
Other steps include thorough washing of the wound and four doses of rabies vaccine over two weeks.
Results of the trial — the first among kids — have been submitted to the U.S. Food and Drug Administration for review. KEDRAB is not licensed outside the United States.
“Despite the large proportion of pediatric cases, limited safety and efficacy data had previously existed for use in pediatric patients,” said study senior author Dr. James Linakis. He’s a professor of emergency medicine and pediatrics at Brown University’s Warren Alpert Medical School in Providence, R.I.
Dr. Nicholas Hobart-Porter, a pediatric emergency doctor at the Arkansas Children’s Hospital in Little Rock, led the trial.
He said the findings confirm that KEDRAB addresses an unmet need in children who may have been exposed to rabies.
“Evidence from this … trial gives health care providers confidence when preventing this deadly condition in countless numbers of young patients across the U.S.,” Hobart-Porter said in a journal news release. Read more from U.S. News & World Report.
